A new indication
In addition to being used mainly for the treatment of prostate cancer, the three-month formulation of triptorelin has been registered in several European countries to treat severe sexual deviation in adult men (e.g. paedophilia).
- First national approval in Sweden in 2006
- Launched in 9 additional EU countries in 2009 + in Switzerland in 2014